Read our latest updates & insights

Pharm-Olam announces it has been selected by the US Department of Defense to lead and provide full service clinical trial support of Ph II/III clinical trials of adalimumab as a COVID-19 therapeutic.

Innovent announces it has signed a licensing agreement with PT Etana Biotechnologies for Byvasda® (biosimilar bevacizumab). Under the agreement, Etana will receive commercialisation rights in Indonesia in exchange for milestone payments and double-digit royalties on net sal...

Prestige Biopharma announces it is set for an IPO in early February 2021. The IPO is expected to be worth US $348 million, with the majority of the funds to be reinvested in R&D.

Celltrion announces it has submitted an investigational new drug application for Ph III trials of CT-P41 (proposed denosumab biosimilar).

Kamada announces it has entered into agreements with two undisclosed international pharmaceutical companies to commercialise three biosimilar product candidates in Israel.

A new study reviews the use of rituximab as an alternative treatment option for the management of multiple sclerosis (MS). While not approved for MS, there is evidence of significant off-label usage of rituximab for the treatment of MS in some Northern European countries.

ADQ announces it will acquire Pharmax Pharmaceuticals, as well as investing in a minority stake in Biocon Biologics.

The Centre for Biosimilars reported a study presented at the 2020 San Antonio Breast Cancer Symposium found strong uptake of Amgen’s Kanjinti® (biosimilar trastuzumab) in Europe.